Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.58 |
| ▸ | HTR1A | P08908 | 6/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.51 |
| ▸ | HTR1D | P28221 | 4/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11177660 | 1.00 | HTR2A (0.58) | HTR2AHTR1AHTR6HTR1DHTR2B | |
| Fumaric Acid SCHEMBL7382417 | 0.88 | KDM4E (0.55) | HTR2AHTR1AHTR6HTR1DHTR2B | |
| Fumaric Acid SCHEMBL7382409 | 0.88 | KDM4E (0.55) | HTR2AHTR1AHTR6HTR1DHTR2B | |
| SCHEMBL1754917 | 0.83 | AHR (0.47) | HTR2AHTR1AHTR6HTR2BKDM4E | |
| SCHEMBL29443976 | 0.83 | AHR (0.47) | HTR2AHTR1AHTR6HTR2BKDM4E | |
| SCHEMBL7429830 | 0.82 | HTR2A (0.63) | HTR2AHTR1AHTR6HTR1DHTR2B | |
| SCHEMBL3792774 | 0.80 | AHR (0.44) | HTR2AHTR1ACYP2D6CYP2C9CYP3A4 | |
| SCHEMBL1118996 | 0.79 | HTR2A (0.88) | HTR2AHTR1AHTR6HTR1DHTR2B | |
| SCHEMBL7498963 | 0.79 | HTR1A (0.68) | HTR2AHTR1AHTR6HTR1DHTR2B | |
| SCHEMBL5616200 | 0.79 | SLC6A4 (0.43) | HTR1ABCHESLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12580049-B2 | Tumor microenvironment-based methods for assessing CAR-T and other immunotherapies | BOSTONGENE CORPORATION (US) | 2026-03-17 | — | — | US | claimed |
| CN-119909092-A | Therapeutic effect of circular RNA molecular medicine on pulmonary artery high pressure mice | 南开大学 | 2025-05-02 | — | — | CN | claimed |
| US-20250084141-A1 | RNA ENCODING A THERAPEUTIC PROTEIN | CureVac SE (DE) | 2025-03-13 | — | — | US | claimed |
| CN-115367909-A | Hydroxyl oxidation device for treating complex wastewater and treatment method thereof | 江苏恩飞特环保工程有限公司 | 2022-11-22 | — | — | CN | claimed |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | THE GENERAL HOSPITAL CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| CN-122075492-A | Application of tetrandrine in preparation of anti-akabane virus medicine | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260139301-A1 | CATALYTIC DE-CROSSLINKING OF SAMPLES FOR IN SITU ANALYSIS | 10X GENOMICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-117084996-B | Curcumin composite nanoparticle with stable drug loading and preparation method thereof | 长沙理工大学 | 2026-05-12 | — | — | CN | disclosed |
| US-12622978-B2 | Binding agents and uses thereof for central nervous system delivery | ARUNA BIO, INC. | 2026-05-12 | — | — | US | disclosed |
| CN-119339808-B | Antigen peptide screening method and evaluation method based on immunogenicity | 北京市神经外科研究所 | 2026-05-12 | — | — | CN | disclosed |
| US-12611414-B2 | Cysteinyl-proresolving mediators that promote resolution of infection and organ protection | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12516369-B1 | Catalytic de-crosslinking of samples for in situ analysis | 10X GENOMICS, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| EP-3632150-B1 | METHOD AND APPARATUS FOR DYNAMIC PROTECTION AREA (DPA) PROTECTION | ERICSSON TELEFON AB L M (SE) | 2022-05-04 | — | — | EP | disclosed |
| CN-109574907-B | Indolone compound and preparation method and application thereof | 天津科技大学 | 2022-05-03 | — | — | CN | disclosed |
| CN-114316081-A | A sulfated polysaccharide of Botrytis longipedicularis with SARS-CoV-2 inhibiting activity, and its preparation method and application | 大连工业大学 | 2022-04-12 | — | — | CN | disclosed |
| CN-114295443-A | Environment-friendly dewaxing transparent reagent and preparation method and application thereof | 广州安必平医药科技股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20220096520-A1 | MODIFIED PROTEINS AND ASSOCIATED METHODS OF TREATMENT | ARCTURUS THERAPEUTICS, INC. | 2022-03-31 | — | — | US | disclosed |
| US-11282132-B2 | Frameworks and methodologies configured to enable generation and utilisation of three-dimensional body scan data | mPort Ltd (AU) | 2022-03-22 | — | — | US | disclosed |
| US-20220073891-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
| CN-112442019-B | Seven-methine functional cyanine dye based on click activation and large steric hindrance aggregation quenching resistance, and preparation method and application thereof | 西安电子科技大学 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622978-B2 | Binding agents and uses thereof for central nervous system delivery | BST2, SYNGR2, VAMP8 | HTR2A 1363/4885HTR1A 2958/4885HTR6 577/4885 |
| US-20220073891-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORS | METTL16, ADAR, RNGTT | HTR2A 1936/4885HTR1A 3302/4885HTR6 1773/4885 |
| US-12580049-B2 | Tumor microenvironment-based methods for assessing CAR-T and other immunotherapies | CCR8, LEF1, CXCL12 | HTR2A 3981/4885HTR1A 4023/4885HTR6 3784/4885 |
| US-12637674-B2 | Inhibition of lncExACT1 to treat heart disease | DACH1, TNNT2, CDH1 | HTR2A 783/4885HTR1A 1335/4885HTR6 1409/4885 |
| US-20260139301-A1 | CATALYTIC DE-CROSSLINKING OF SAMPLES FOR IN SITU ANALYSIS | RNGTT, NSUN2, POLL | HTR2A 4043/4885HTR1A 4194/4885HTR6 1953/4885 |
| US-20220096520-A1 | MODIFIED PROTEINS AND ASSOCIATED METHODS OF TREATMENT | UBQLN2, UBQLN1, UPF1 | HTR2A 3971/4885HTR1A 4465/4885HTR6 4025/4885 |
| US-20250084141-A1 | RNA ENCODING A THERAPEUTIC PROTEIN | NSUN3, SARNP, TRDMT1 | HTR2A 4569/4885HTR1A 4543/4885HTR6 4050/4885 |
| US-12611414-B2 | Cysteinyl-proresolving mediators that promote resolution of infection and organ protection | CYSLTR2, FPR2, FPR3 | HTR2A 529/4885HTR1A 1702/4885HTR6 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.